Oncternal Therapeutics to Update Business, Report Q2 2024 Financial Results

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a biopharmaceutical firm in the clinical stage dedicated to innovative cancer treatments, has announced plans to release its financial results for the second quarter of 2024 following the closure of U.S. financial markets on Thursday, August 8, 2024. The company's management will conduct a webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial outcomes and provide a business update. The live webcast will be accessible online at investor.oncternal.com and will remain available for at least 30 days.

About Oncternal Therapeutics

Oncternal Therapeutics is a biopharmaceutical company focused on developing novel oncology therapies to address critical unmet medical needs in cancer treatment. The company's research and development efforts are centered on targeting promising, yet underexplored biological pathways that play a role in cancer development and progression. The primary focus is on hematological malignancies and prostate cancer.

Pipeline and Clinical Studies

ONCT-534: This investigational drug is a dual-action androgen receptor inhibitor (DAARI) showing preclinical efficacy in prostate cancer models. It targets both unmutated androgen receptors and various forms of androgen receptor aberrations. ONCT-534 is being investigated as a potential treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) who have developed resistance to existing androgen receptor pathway inhibitors. The drug has been tested in Study ONCT-534-101 (NCT05917470), which has completed enrollment and dosing in six dose cohorts.

ONCT-808: ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy targeting the Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), utilizing the binding domain from zilovertamab. Preclinical models have shown that ONCT-808 is effective against various hematological malignancies and solid tumors, specifically targeting cancer cells expressing ROR1. Oncternal has optimized a manufacturing process that potentially reduces the production time for individual CAR T therapies compared to currently approved products. Patients have been dosed under Study ONCT-808-101 (NCT05588440) for relapsed or refractory aggressive B-cell lymphoma, including those who have failed previous CD19 CAR T treatments.

Zilovertamab: This investigational monoclonal antibody aims to inhibit the function of ROR1. Zilovertamab has been tested in Phase 1/2 Study CIRM-0001 (NCT03088878) in combination with ibrutinib for treating mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and marginal zone lymphoma (MZL). The study showed a 100% progression-free survival (PFS) rate at 42 months in CLL patients with p53 mutations/del(17p), a group underserved by current treatments. Additionally, zilovertamab is being evaluated in an investigator-initiated Phase 1b study with docetaxel for patients with metastatic castration-resistant prostate cancer (NCT05156905).

Oncternal Therapeutics continues to focus on advancing its oncology pipeline, aiming to address significant gaps in current cancer treatment options.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!